The recent, and quite rapid, approval of Gilead Sciences, Inc.’s Veklury (remdesivir) highlights the agency’s willingness to prioritize therapies for emerging infectious disease threats.
Veklury cleared the agency on 22 October 2020, just 77 days after NDA submission for treatment of COVID-19 requiring hospitalization....






